Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

MDS 2025 Novel Drug With New Mechanism Promising for PD Fluctuations Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s disease ...

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative ...

Paris Margaritis, DPhil, is a professional with over 28 years of experience in AAV gene therapy for hemophilia. A key focus of his work has been treating hemophilia patients with inhibitors. He earned ...

n (Participants) = number of study participants with at least one event in the corresponding category n (Events) = number of events in the corresponding category and treatment group N = total number ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Addex Therapeutics ( ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) saw its stock advance 5% after releasing positive topline data from a Phase 2 study evaluating ANAVEX®3-71 in adults with schizophrenia who were already ...